78,522 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Leeward Investments LLC MA

Leeward Investments LLC MA acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 78,522 shares of the medical equipment provider’s stock, valued at approximately $5,610,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Trust Asset Management LLC purchased a new stake in Hologic in the 4th quarter valued at approximately $204,000. Stevens Capital Management LP purchased a new stake in Hologic in the 4th quarter valued at approximately $806,000. Meritage Portfolio Management boosted its holdings in Hologic by 6.6% in the 4th quarter. Meritage Portfolio Management now owns 141,485 shares of the medical equipment provider’s stock valued at $10,109,000 after purchasing an additional 8,806 shares in the last quarter. Corbyn Investment Management Inc. MD purchased a new stake in Hologic in the 4th quarter valued at approximately $247,000. Finally, GAMMA Investing LLC acquired a new stake in shares of Hologic during the 4th quarter valued at approximately $155,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on HOLX shares. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Wednesday, April 10th. Finally, UBS Group lifted their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus target price of $87.00.

Hologic Price Performance

HOLX stock traded up $0.27 on Friday, reaching $75.98. The company had a trading volume of 919,462 shares, compared to its average volume of 1,769,007. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The company’s fifty day moving average is $76.03 and its 200 day moving average is $72.78. The company has a market cap of $17.83 billion, a P/E ratio of 36.01, a PEG ratio of 2.60 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same quarter in the prior year, the company earned $1.07 EPS. Hologic’s revenue was down 5.7% on a year-over-year basis. On average, research analysts forecast that Hologic, Inc. will post 4.01 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock valued at $2,473,443 in the last quarter. 1.75% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.